Moderna, Inc. (MRNA)
Automate Your Wheel Strategy on MRNA
With Tiblio's Option Bot, you can configure your own wheel strategy including MRNA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MRNA
- Rev/Share 8.1839
- Book/Share 26.0777
- PB 1.0327
- Debt/Equity 0.074
- CurrentRatio 4.2182
- ROIC -0.3311
- MktCap 10414962060.0
- FreeCF/Share -10.4249
- PFCF -2.5882
- PE -3.0965
- Debt/Assets 0.0586
- DivYield 0
- ROE -0.301
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | MRNA | Citigroup | -- | Neutral | -- | $40 | March 13, 2025 |
| Downgrade | MRNA | Barclays | Overweight | Equal Weight | $111 | $45 | Feb. 18, 2025 |
| Downgrade | MRNA | Goldman | Buy | Neutral | $99 | $51 | Jan. 29, 2025 |
| Downgrade | MRNA | Argus | Buy | Hold | -- | -- | Dec. 18, 2024 |
| Resumed | MRNA | BofA Securities | -- | Underperform | -- | $41 | Dec. 10, 2024 |
| Initiation | MRNA | Bernstein | -- | Market Perform | -- | $55 | Oct. 17, 2024 |
| Downgrade | MRNA | Jefferies | Buy | Hold | $120 | $65 | Sept. 13, 2024 |
| Downgrade | MRNA | JP Morgan | Neutral | Underweight | $88 | $70 | Sept. 13, 2024 |
| Downgrade | MRNA | Oppenheimer | Outperform | Perform | -- | -- | Sept. 13, 2024 |
| Upgrade | MRNA | HSBC Securities | Reduce | Hold | -- | $82 | Aug. 28, 2024 |
News
Moderna, Inc. (MRNA) Bernstein 41st Annual Strategic Decisions Conference Call Transcript
Published: May 29, 2025 by: Seeking Alpha
Sentiment: Neutral
Moderna, Inc. (NASDAQ:MRNA ) Bernstein 41st Annual Strategic Decisions Conference Call May 29, 2025 10:00 AM ET Company Participants Stephane Bancel - CEO & Director Conference Call Participants Courtney Breen - Bernstein Courtney Breen So I am thrilled to be here today with Stephane Bancel from Moderna. My name is Courtney Breen.
Read More
U.S. Govt. Cancels $766M Funding Contract for Moderna's Bird Flu Shot
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
The government scraps funding deal for MRNA's bird flu shot, despite encouraging safety and efficacy data from early clinical studies on the vaccine.
Read More
Cautious? Risky? Our Volatility Scorecard Can Help
Published: May 27, 2025 by: Schaeffers Research
Sentiment: Neutral
Our volatility scorecard has a pretty good feel for the market right now.
Read More
Will Moderna's Rally Continue?
Published: May 26, 2025 by: Forbes
Sentiment: Positive
Moderna (NASDAQ: MRNA) has caught the market off guard with a significant recovery in recent days – reaching current levels of approximately $27 after hitting a five-year low of $23.15 last week – following the FDA's decision to continue advising annual COVID-19 vaccinations for high-risk populations. However, this abrupt rally appears to be a singular occurrence – competitors such as Pfizer (NYSE: PFE), Sarepta Therapeutics (NASDAQ: SRPT), and CureVac (NASDAQ:CVAC) did not replicate Moderna's increase – implying the rise was primarily fueled by the FDA guidance rather than a wider sector uptrend.
Read More
MRNA Stock Down on Withdrawal of FDA Filing for COVID-Flu Combo Shot
Published: May 22, 2025 by: Zacks Investment Research
Sentiment: Neutral
Moderna's voluntary withdrawal of the filing stems from the FDA's request for vaccine efficacy data from a phase III study on the experimental flu shot.
Read More
Moderna Stock Looks Ripe for a Short Squeeze
Published: May 22, 2025 by: MarketBeat
Sentiment: Neutral
Moderna Inc. NASDAQ: MRNA is down 35% in 2025, making it one of the worst-performing stocks among medical stocks and the broader market. Not surprisingly, the stock is down over 80% in the last 12 months.
Read More
MRNA, PFE Stocks Jump Despite FDA's Stricter Standards for COVID-19 Shots
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Neutral
Though the new FDA rules limit access to COVID-19 booster vaccines, the commitment to high-risk groups lifts Moderna, Pfizer and BioNTech stocks.
Read More
Moderna withdraws application for COVID-flu combination vaccine
Published: May 21, 2025 by: Reuters
Sentiment: Negative
Moderna said on Wednesday it had withdrawn the pending application for its flu and COVID combination vaccine candidate for adults aged 50 years and older.
Read More
Moderna shares surge as new FDA vaccine framework eases investor concerns
Published: May 20, 2025 by: Proactive Investors
Sentiment: Positive
Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares jumped more than 6.5% on Tuesday after the US Food and Drug Administration unveiled a new framework for COVID-19 vaccine approvals that analysts said largely maintains the status quo for the company's core market. The FDA's updated guidance does not change how COVID-19 vaccines are authorized for individuals aged 65 and older or those aged six months to 64 years who are at high risk.
Read More
Top Stock Movers Now: Viking, Moderna, Uber Technologies, and More
Published: May 20, 2025 by: Investopedia
Sentiment: Negative
U.S. equities were lower at midday, dragged by tech and travel stocks. The Dow Jones Industrial Average, S&P 500, and Nasdaq were all lower.
Read More
Moderna: After A Crash From $500 To $25, I'm Buying This "Call Option" On Pandemics And Cancer
Published: May 20, 2025 by: Seeking Alpha
Sentiment: Positive
Moderna's share price has collapsed from $500 to $25, but I believe the selloff is overdone, and the stock is deeply oversold. Short squeeze potential, a robust pipeline, and long-term mRNA/AI opportunities could drive a significant rebound, despite near-term losses and vaccine skepticism. Moderna's strong balance sheet, insider buying, and promising oncology candidates add to my conviction for a small, speculative position.
Read More
Cautious? Risky? Our Volatility Scorecard Can Help
Published: May 13, 2025 by: Schaeffers Research
Sentiment: Neutral
Subscribers to Chart of the Week received this commentary on Sunday, May 11.
Read More
Why Moderna Merged Its Tech and HR Departments
Published: May 12, 2025 by: WSJ
Sentiment: Neutral
The vaccine maker, which has partnered with OpenAI since 2023, is rethinking how it does workforce planning thanks to the growing capabilities of AI and other tech.
Read More
Moderna Sharpens Pipeline Focus as COVID-19 Vaccine Demand Ebbs in Q1
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Moderna plans to launch 10 new marketed products over the next three years, aiming to diversify a revenue base, which is still heavily reliant on COVID-19 vaccine sales.
Read More
Moderna faces long-term threat from NIH's universal vaccine initiative, Jefferies says
Published: May 02, 2025 by: Proactive Investors
Sentiment: Negative
Moderna Inc (NASDAQ:MRNA, ETR:0QF) could face a longer-term threat from a newly announced US government initiative to develop universal vaccines for pandemic-prone viruses, analysts at Jefferies said on Friday. The National Institutes of Health (NIH) unveiled plans this week to build a next-generation vaccine platform aimed at creating broad-spectrum, long-lasting protection against viruses like avian flu and coronaviruses.
Read More
Moderna (MRNA) Reports Q1 Earnings: What Key Metrics Have to Say
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Moderna (MRNA) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Moderna: Regulatory Hurdles And Market Challenges Prompt Downgrade To Sell
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Negative
Moderna's Q1 earnings reveal a significant revenue decline and high cash burn, driven by reduced demand for its COVID-19 vaccine and inventory write-downs. Regulatory setbacks for Moderna's combination flu/COVID-19 vaccine delay its market entry, adding to the company's challenges amid strong competition from other drugmakers. Despite cost-cutting efforts, Moderna's financial health is strained, with high costs and low margins, leading to a downgrade to "Sell" or "market underperform."
Read More
Moderna Beats on Q1 Earnings, Lags on Revenues, Focuses on Cost Cuts
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
MRNA reports mixed Q1 results. The company reiterates 2025 sales guidance but announces a cost-cutting initiative to reduce expenses significantly by 2027.
Read More
Moderna, Inc. (MRNA) Q1 2025 Earnings Call Transcript
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Moderna, Inc. (NASDAQ:MRNA ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Lavina Talukdar - Senior Vice President, Investor Relations Stephane Bancel - Chief Executive Officer Jamey Mock - Chief Financial Officer Stephen Hoge - President Conference Call Participants Salveen Richter - Goldman Sachs Tyler Van Buren - TD Cowen Cory Kasimov - Evercore ISI Courtney Breen - Bernstein Dick Gottfred - William Blair Gena Wang - Barclays Operator Good day, and thank you for standing by. Welcome to the Moderna First Quarter 2025 Conference Call.
Read More
Moderna (MRNA) Reports Q1 Loss, Lags Revenue Estimates
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative
Moderna (MRNA) came out with a quarterly loss of $2.52 per share versus the Zacks Consensus Estimate of a loss of $2.92. This compares to loss of $3.07 per share a year ago.
Read More
Moderna Posts Loss, Citing Seasonality of Respiratory Business
Published: May 01, 2025 by: WSJ
Sentiment: Negative
Moderna logged a first-quarter loss as revenue fell, dragged down by lower product sales, though the company said it expects demand to increase during cold and flu season later this year.
Read More
Moderna Reports First Quarter 2025 Financial Results and Provides Business Updates
Published: May 01, 2025 by: Accesswire
Sentiment: Neutral
Reports first quarter revenues of $0.1 billion, GAAP net loss of $(1.0) billion and GAAP EPS of $(2.52) Reiterates 2025 expected revenue range of $1.5 to $2.5 billion and 2025 year-end cash balance of approximately $6 billion Announces reduction of $1.4 to $1.7 billion in estimated GAAP operating costs by 2027 Advancing up to 10 products toward approval, including multiple oncology candidates CAMBRIDGE, MA / ACCESS Newswire / May 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the first quarter of 2025. "In the first quarter, we continued to execute with financial discipline, …
Read More
Down 36%, Is Moderna a Buy on the Dip?
Published: April 28, 2025 by: The Motley Fool
Sentiment: Neutral
In many ways, the pandemic is becoming a faded memory. With that, a major pandemic star -- biotech Moderna (MRNA -0.79%) -- also seems to be disappearing from the world's attention.
Read More
Market Sell-Off: 2 Stocks Down 17% and 36% This Year to Buy and Hold
Published: April 26, 2025 by: The Motley Fool
Sentiment: Positive
What should investors do during a stock-market correction? One great strategy is to go shopping.
Read More
Can Moderna Keep the Beat Streak Alive This Earnings Season?
Published: April 25, 2025 by: Zacks Investment Research
Sentiment: Positive
When MRNA reports first-quarter earnings, investors will likely focus on pipeline updates.
Read More
Where Will Moderna Be in 5 Years?
Published: April 20, 2025 by: The Motley Fool
Sentiment: Positive
In the early days of the COVID-19 pandemic, Moderna (MRNA -1.89%) was a top performer, from both a share-price and an earnings perspective. As one of the leading coronavirus vaccine companies, the biotech brought in billions of dollars in annual earnings and saw its stock price jump more than 2,300% from January 2020 through early August of 2021.
Read More
Vaccine Stocks Rise on Growing Threat of Bird Flu Infections
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Negative
The Biden administration is reportedly in talks with vaccine makers Moderna (MRNA) and Pfizer (PFE) to develop bird flu vaccines over increasing fears of widespread transmission of the infection.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: April 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Read More
FDA News Just Shook Moderna. Is the Stock One to Avoid or a Bad-News Buy?
Published: April 03, 2025 by: The Motley Fool
Sentiment: Positive
Moderna (MRNA 2.21%) has gone through its share of ups and downs in recent years, from posting soaring coronavirus vaccine revenue a few years ago to seeing demand for that product sink in the later stages of the coronavirus pandemic. Now, the biotech is trying to show the world that it can expand beyond coronavirus prevention as it has a full pipeline of programs ranging from latent viruses and rare diseases to cancer.
Read More
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks
Published: April 01, 2025 by: CNBC
Sentiment: Negative
Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'
Read More
About Moderna, Inc. (MRNA)
- IPO Date 2018-12-07
- Website https://www.modernatx.com
- Industry Biotechnology
- CEO Mr. Stephane Bancel
- Employees 5800